^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

NIB103

i
Other names: NIB103, TAK-103, NIB-103
Associations
Company:
Noile-Immune Biotech
Drug class:
Mesothelin-targeted CAR-T immunotherapy
Associations
11ms
A Study of TAK-103 in Adult With Solid Tumors (clinicaltrials.gov)
P1, N=2, Active, not recruiting, Takeda | Recruiting --> Active, not recruiting | N=21 --> 2
Enrollment closed • Enrollment change • Metastases
|
MSLN (Mesothelin)
|
MSLN expression
|
NIB103
over1year
A Study of TAK-103 in Adult With Solid Tumors (clinicaltrials.gov)
P1, N=21, Recruiting, Takeda | Trial completion date: Oct 2026 --> Oct 2027 | Trial primary completion date: Oct 2026 --> Oct 2027
Trial completion date • Trial primary completion date • Metastases
|
MSLN (Mesothelin)
|
MSLN expression
|
NIB103
over2years
A Study of TAK-103 in Adult With Solid Tumors (clinicaltrials.gov)
P1, N=21, Recruiting, Takeda | Not yet recruiting --> Recruiting
Enrollment open
|
MSLN (Mesothelin)
|
MSLN expression
|
NIB103
almost3years
New P1 trial
|
MSLN (Mesothelin)
|
MSLN expression
|
NIB103